keyword
MENU ▼
Read by QxMD icon Read
search

multiple myeloma fracture

keyword
https://www.readbyqxmd.com/read/29776381/wnt-signaling-in-multiple-myeloma-a-central-player-in-disease-with-therapeutic-potential
#1
REVIEW
Ingrid Spaan, Reinier A Raymakers, Anja van de Stolpe, Victor Peperzak
Multiple myeloma is the second most frequent hematological malignancy in the western world and remains incurable, predominantly due to acquired drug resistance and disease relapse. The highly conserved Wnt signal transduction pathway, which plays a key role in regulating cellular processes of proliferation, differentiation, migration, and stem cell self-renewal, is associated with multiple aspects of disease. Bone homeostasis is severely disturbed by Wnt antagonists that are secreted by the malignant plasma cells in the bone marrow...
May 18, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29743398/-achievement-of-a-stringent-complete-response-with-low-dose-pomalidomide-monotherapy-in-a-multiple-myeloma-patient
#2
Toshihide Endo, Takashi Hamada, Shimon Otake, Masaru Nakagawa, Yshihito Uchino, Hiromichi Takahashi, Katsuhiro Miura, Noriyoshi Iriyama, Takashi Koike, Kazuya Kurihara, Hiroko Sato, Yoshihiro Hatta, Msamai Takei
An 80-year-old man presented to our hospital with a thoracic vertebrae compression fracture. He was diagnosed with IgG-λ myeloma (International Staging System stage II, Durie-Salmon stage IIIA). Since melphalan-prednisolone (MP) was not effective, we treated him with lenalidomide and low-dose dexamethasone (DEX) (Ld), achieving a partial response. As DEX provoked edema and psychiatric symptoms, the patient disagreed with its use, and pomalidomide (POM) monotherapy was initiated. Although the POM dosage was reduced to 1-2 mg/day due to somnolence, which was reported as an adverse event, stringent complete response (sCR) was achieved and sustained for 10 months following 11 cycles of low-dose POM monotherapy...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29721251/bone-targeted-agents-in-multiple-myeloma
#3
Hiroko Nishida
Osteolytic bone disease, characterized by bone pain, increased risk of pathologic fractures, tumor-induced hypercalcemia known as skeletal-related events (SREs), is a frequent complication of patients with multiple myeloma (MM) and persists even in the absence of active disease, resulting in a major cause of morbidity and mortality. The interaction between myeloma cells and their surrounding cells in the bone marrow (BM) microenvironment promotes both myeloma cell growth and bone destruction and forms the vicious cycle of MM bone disease...
March 2, 2018: Hematology Reports
https://www.readbyqxmd.com/read/29701006/nanotherapeutics-for-multiple-myeloma
#4
REVIEW
Alexander Zheleznyak, Monica Shokeen, Samuel Achilefu
Multiple myeloma (MM) is an age-related hematological malignancy with an estimated 30,000 new cases and 13,000 deaths per year. A disease of antibody-secreting malignant plasma B-cells that grow primarily in the bone marrow (BM), MM causes debilitating fractures, anemia, renal failure, and hypercalcemia. In addition to the abnormal genetic profile of MM cells, the permissive BM microenvironment (BMM) supports MM pathogenesis. Although advances in treatment options have significantly enhanced survival in MM patients, transient perfusion of small-molecule drugs in the BM does not provide sufficient residence to enhance MM cell-drug interaction, thus allowing some myeloma cells to escape the first line of treatment...
April 26, 2018: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/29690814/concurrent-progressive-multifocal-leukoencephalopathy-and-central-nervous-system-infiltration-by-multiple-myeloma-a-case-report
#5
Yanira Ruiz-Heredia, Beatriz Sanchez-Vega, Santiago Barrio, María Linares, Inmaculada Rapado, Esteban Braggio, Keith Stewart, M Dolores Folgueira, Ana Ramos, Luis Collado, Juan Ruiz, Oscar Toldos, Aurelio Hernandez-Lain, Joaquin Martinez-Lopez
Progressive multifocal leukoencephalopathy rarely occurs in patients with multiple myeloma. Intracranial central nervous system invasion is also an uncommon event in multiple myeloma, occurring in less than 1% of cases. We describe herein an exceptional case of coexisting progressive multifocal leukoencephalopathy and intraparenchymal central nervous system myeloma infiltration. A 73-year-old woman with relapsed multiple myeloma was treated with 15 cycles of lenalidomide and dexamethasone, but therapy had to be stopped because of a hip fracture after a fall...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29571273/economic-burden-of-skeletal-related-events-in-patients-with-multiple-myeloma-analysis-of-us-commercial-claims-database
#6
Debajyoti Bhowmik, Dionne M Hines, Michele Intorcia, Rolin L Wade
AIMS: To estimate incremental healthcare resource utilization (HRU) and costs associated with skeletal-related events (SREs) secondary to multiple myeloma (MM), and HRU and cost differences in patients with one vs multiple SREs. METHODS: Adults with MM diagnosis between January 1, 2010-December 31, 2014, with benefits coverage ≥12 months pre- and ≥6 months post-diagnosis were followed to last coverage date or December 31, 2015, excluding patients with prior anti-myeloma treatment or cancers...
April 12, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29530691/evaluation-of-the-relevance-of-surgery-in-patients-with-multiple-myeloma-harboring-symptomatic-spinal-involvement-a-retrospective-case-series
#7
Mathilde Quidet, Fahed Zairi, Eileen Boyle, Thierry Facon, Marie-Hélène Vieillard, François Machuron, Jean-Paul Lejeune, Richard Assaker
BACKGROUND: Multiple myeloma spinal involvement can lead to bone fractures and neurologic impairment that can severely alter quality of life. The role of surgery is controversial, given its high morbidity, and the lack of evidence. We hereby aim to evaluate efficacy and safety of surgery in the management of symptomatic spinal lesions in patients with multiple myeloma. METHODS: We included all patients operated on for a myeloma-related spinal lesion in our institution between 2007 and 2015...
March 9, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29495905/possible-targets-to-treat-myeloma-related-osteoclastogenesis
#8
Marina Bolzoni, Denise Toscani, Paola Storti, Valentina Marchica, Federica Costa, Nicola Giuliani
Bone destruction is the hallmark of multiple myeloma (MM). About 80% of MM patients at diagnosis presents myeloma bone disease (MBD) leading to bone pain and pathological fractures, significantly affecting patients' quality of life. Bisphosphonates are the treatment of choice for MBD, but osteolytic lesions remain a critical issue in the current management of MM patients. Several studies clarified the mechanisms involved in MM-induced osteoclast formation and activation, leading to the identification of new possible targets and the development of better bone-directed therapies, that are discussed in this review...
April 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29444353/healthcare-resource-utilisation-associated-with-skeletal-related-events-in-european-patients-with-multiple-myeloma-results-from-a-prospective-multinational-observational-study
#9
John Ashcroft, Ignacio Duran, Herbert Hoefeler, Vito Lorusso, Diana Lueftner, Marco Campioni, Michele Intorcia, Amit Bahl
OBJECTIVES: Patients with multiple myeloma (MM) often experience debilitating skeletal-related events (SREs: pathologic fracture, radiation to bone [RB], surgery to bone [SB] or spinal cord compression [SCC]). This is the first comprehensive, prospective, observational analysis of healthcare resource utilisation (HRU), independently attributed to SREs by investigators, in patients with MM. METHODS: Eligible patients had lytic bone lesions, life expectancy ≥6 months, Eastern Cooperative Oncology Group performance status ≤2 and ≥1 SRE in the 97 days before enrolment...
May 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29429912/denosumab-versus-zoledronic-acid-in-bone-disease-treatment-of-newly-diagnosed-multiple-myeloma-an-international-double-blind-double-dummy-randomised-controlled-phase-3-study
#10
Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Brian Durie, Wojciech Legieć, Marta Krejčí, Kamel Laribi, Li Zhu, Paul Cheng, Douglas Warner, G David Roodman
BACKGROUND: Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a monoclonal antibody targeting RANKL, reduces skeletal-related events associated with bone lesions or metastases in patients with advanced solid tumours. This study aimed to assess the efficacy and safety of denosumab compared with zoledronic acid for the prevention of skeletal-related events in patients with newly diagnosed multiple myeloma...
March 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29422089/cement-pulmonary-embolism-as-a-complication-of-percutaneous-vertebroplasty-in-cancer-patients
#11
Asem Mansour, Nayef Abdel-Razeq, Hussein Abuali, Mohammad Makoseh, Nouran Shaikh-Salem, Kamelah Abushalha, Samer Salah
BACKGROUND: Vertebroplasty is a minimally invasive procedure commonly performed for vertebral compression fractures secondary to osteoporosis or malignancy. Leakage of bone cement into the paravertebral venous system and cement pulmonary embolism (cPE) are well described, mostly in patients with osteoporosis. Little is known about the clinical sequelae and outcomes in cancer patients. In this study, we report our experience with cPE following vertebroplasty performed in cancer patients...
February 8, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/29388036/anaplastic-plasmacytoma-a-rare-tumor-presenting-as-a-pathological-fracture-in-a-younger-adult
#12
Robert W Morris, Varsha Kumar, Ali G Saad
Solitary plasmacytoma is the rarest type of plasma cell neoplasm, and the anaplastic form is even more uncommon. Plasmacytoma most commonly originates in bone and predominantly affects older patients. We describe the case of a 35-year-old woman with solitary osseous anaplastic plasmacytoma that presented initially with a pathological fracture following minor trauma. The patient was immunocompetent and had no predisposing conditions for a plasma cell tumor. Left lower extremity radiographs revealed an oblique fracture of the distal femur, and CT imaging indicated a primary osseous lesion at the fracture site...
January 31, 2018: Skeletal Radiology
https://www.readbyqxmd.com/read/29360160/trends-in-multiple-myeloma-presentation-management-cost-of-care-and-outcomes-in-the-medicare-population-a-comprehensive-look-at-racial-disparities
#13
Sikander Ailawadhi, Ryan D Frank, Mayank Sharma, Richa Menghani, M'hamed Temkit, Shumail Paulus, Nandita Khera, Shahrukh Hashmi, Pooja Advani, Abhisek Swaika, Aneel Paulus, Nabeel Aslam, Taimur Sher, Vivek Roy, Gerardo Colon-Otero, Asher Chanan-Khan
BACKGROUND: Outcomes have improved significantly in multiple myeloma (MM), but racial disparities in health care access and survival exist. A comprehensive analysis exploring MM care and racial disparities is warranted. METHODS: Patients with MM from 1991 to 2010 in the Surveillance, Epidemiology, and End Results-Medicare database were evaluated for racial trends in clinical myeloma-defining events (MDEs), the receipt of treatment (drugs and stem cell transplantation; [SCT]), the cost of care, and overall survival (OS)...
April 15, 2018: Cancer
https://www.readbyqxmd.com/read/29341831/role-of-bone-modifying-agents-in-multiple-myeloma-american-society-of-clinical-oncology-clinical-practice-guideline-update
#14
Kenneth Anderson, Nofisat Ismaila, Patrick J Flynn, Susan Halabi, Sundar Jagannath, Mohammed S Ogaily, Jim Omel, Noopur Raje, G David Roodman, Gary C Yee, Robert A Kyle
Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and observational studies. Results Thirty-five relevant studies were identified, and updated evidence supports the current recommendations. Recommendations For patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29278014/healthcare-resource-utilization-among-patients-with-relapsed-multiple-myeloma-in-the-uk-france-and-italy
#15
Sebastian Gonzalez-McQuire, Kwee Yong, Henri Leleu, Francesco S Mennini, Alain Flinois, Carlotta Gazzola, Paul Schoen, Marco Campioni, Lucy DeCosta, Leah Fink
AIMS: To assess the real-world healthcare resource utilization (HRU) and costs associated with different treatment regimens used in the management of patients with relapsed multiple myeloma in the UK, France, and Italy. METHODS: Retrospective medical chart review of characteristics, time to progression, level of response, HRU during treatment, and adverse events (AEs). Data collection started on June 1, 2015 and was completed on July 15, 2015. In the 3 months before record abstraction, eligible patients had either disease progression after receiving one of their country's most commonly prescribed regimens or had received the best supportive care and died...
January 10, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29229668/multiple-myeloma-and-bone-the-fatal-interaction
#16
Silvia Marino, G David Roodman
Multiple myeloma (MM) is the second-most-common hematologic malignancy and the most frequent cancer to involve bone. MM bone disease (MMBD) has devastating consequences for patients, including dramatic bone loss, severe bone pain, and pathological fractures that markedly decrease the quality of life and impact survival of MM patients. MMBD results from excessive osteoclastic bone resorption and persistent suppressed osteoblastic bone formation, causing lytic lesions that do not heal, even when patients are in complete and prolonged remission...
December 11, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29187931/-diagnostic-and-evolutionary-profile-of-multiple-myeloma-in-senegal-monocentric-study-conducted-from-2005-to-2016
#17
Seynabou Fall, Fatma Dieng, Coumba Diouf, Boundia Djiba, Awa Cheikh Ndao, Fatou Samba Diago Ndiaye
Introduction: Accessibility to innovative multiple myeloma therapies is limited in sub-Saharan Africa. This study aimed to describe the diagnostic and evolutionary features observed during treatment of our patients with myeloma. Methods: We conducted a retrospective, descriptive, analytical study (2005 - 2016) of patients with myeloma included in the study based on International Myeloma Working Group (IMWG) Criteria (2003,2014) at the Hopital Aristide Le Dantec (Senegal)...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/29175022/biology-and-treatment-of-myeloma-related-bone-disease
#18
Evangelos Terpos, Dimitrios Christoulas, Maria Gavriatopoulou
Myeloma bone disease (MBD) is the most common complication of multiple myeloma (MM), resulting in skeleton-related events (SREs) such as severe bone pain, pathologic fractures, vertebral collapse, hypercalcemia, and spinal cord compression that cause significant morbidity and mortality. It is due to an increased activity of osteoclasts coupled to the suppressed bone formation by osteoblasts. Novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition have recently been described, including the receptor activator of nuclear factor-kB ligand/osteoprotegerin pathway, activin-A and the wingless-type signaling inhibitors, dickkopf-1 (DKK-1) and sclerostin...
March 2018: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29172311/case-report-metastatic-infratemporal-soft-tissue-myeloma-presenting-as-a-numb-lower-lip
#19
Niamh Rice, Badrinarayanan Srinivasan, David Macpherson
This is a case of a patient presenting to his general dental practitioner (GDP) with altered sensation in his lower lip with no obvious cause. Due to a prompt referral, the patient was investigated and diagnosed with an extramedullary presentation of multiple myeloma. A numb lip can present in general dental practice, although this is not common. There are several causes, for example, dental infection or fractured mandible. Clinical relevance: It is very important for the dental practitioner to recognize when there could be a potential sinister underlying cause and prompt referral, under the two week rule referral system, is indicated...
January 2017: Dental Update
https://www.readbyqxmd.com/read/29105945/role-of-bmi-and-age-in-predicting-pathologic-vertebral-fractures-in-newly-diagnosed-multiple-myeloma-patients-a-retrospective-cohort-study
#20
Yi-Lun Chen, Yao-Chung Liu, Chia-Hung Wu, Chiu-Mei Yeh, Hsun-I Chiu, Gin-Yi Lee, Yu-Ting Lee, Pei Hsu, Ting-Wei Lin, Jyh-Pyng Gau, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Jin-Hwang Liu, Chia-Jen Liu
Vertebral fractures affect approximately 30% of myeloma patients and lead to a poor impact on survival and life quality. In general, age and body mass index (BMI) are reported to have an important role in vertebral fractures. However, the triangle relationship among age, BMI, and vertebral fractures is still unclear in newly diagnosed multiple myeloma (NDMM) patients. This study recruited consecutive 394 patients with NDMM at Taipei Veterans General Hospital between January 1, 2005 and December 31, 2015. Risk factors for vertebral fractures in NDMM patients were collected and analyzed...
November 6, 2017: Hematological Oncology
keyword
keyword
66225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"